The earnings call reflects strong growth and expansion for VYVGART across global markets and indications, supported by financial performance and pipeline advancements. However, challenges include market dynamics in China, increased gross to net adjustments, and ongoing safety monitoring in CIDP.

Company Guidance

During the call, Argenx provided extensive guidance on their financial and operational performance. They reported a 97% year-over-year growth in VYVGART sales, achieving $967 million in total operating income for the second quarter of 2025. The growth was driven by $949 million in product net sales, with $802 million from the U.S. market alone. Argenx highlighted the significant progress in treating 15,000 patients globally, including 2,500 with CIDP, just one year into the product's launch. The company aims to expand its patient base to 50,000 by 2030. They also discussed the promising developments in their pipeline, with three Phase III assets, including efgartigimod, advancing across multiple indications. Argenx emphasized their robust financial position, with a $3.9 billion cash balance, and their commitment to innovation and long-term growth, all while maintaining a net revenue per patient consistent with previous guidance despite increased gross-to-net adjustments.

Exceptional Year-over-Year Growth for VYVGART

VYVGART achieved a 97% year-over-year growth across all approved indications, with 15,000 patients globally being treated, including 2,500 CIDP patients just one year into the launch.

Strong Financial Performance

Total operating income in Q2 2025 was $967 million, reflecting a 97% growth compared to the previous year, with $949 million in product net sales and a 19% quarter-over-quarter growth.

Global Market Expansion

VYVGART saw growth across all regions, with U.S. product net sales at $802 million, Japan at $52 million, and significant growth in Europe, Canada, and partner markets.

Introduction of Prefilled Syringe

The launch of the prefilled syringe has driven new patient starts and prescriber demand, with 50% of PFS patients being new to VYVGART.

Pipeline and Innovation Expansion

Advancing 4 new molecules into the pipeline, including ARGX-119, and collaborations to enhance capabilities, such as with Unnatural Products.

Argenx Se (ARGX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARGX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	4.41 / -	1.39	―	―	―
Jul 31, 2025	2025 (Q2)	3.09 / 3.74	0.45	731.11% (+3.29)
May 08, 2025	2025 (Q1)	2.42 / 2.58	-1.04	348.08% (+3.62)
Feb 27, 2025	2024 (Q4)	1.71 / 11.79	-1.68	801.79% (+13.47)
Oct 31, 2024	2024 (Q3)	0.15 / 1.39	-1.25	211.20% (+2.64)
Jul 25, 2024	2024 (Q2)	-0.90 / 0.45	-1.69	126.63% (+2.14)
May 09, 2024	2024 (Q1)	-0.77 / -1.04	-0.52	-100.00% (-0.52)
Feb 29, 2024	2023 (Q4)	-1.32 / -1.68	-0.7	-140.00% (-0.98)
Oct 31, 2023	2023 (Q3)	-1.45 / -1.25	-4.26	70.66% (+3.01)
Jul 27, 2023	2023 (Q2)	-1.71 / -1.69	-3.81	55.64% (+2.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ARGX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$598.89	$670.33	+11.93%
May 08, 2025	$622.93	$569.12	-8.64%
Feb 27, 2025	$623.02	$624.70	+0.27%
Oct 31, 2024	$551.71	$586.30	+6.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Argenx Se (ARGX) report earnings?

Argenx Se (ARGX) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Argenx Se (ARGX) earnings time?

Argenx Se (ARGX) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ARGX EPS forecast?

ARGX EPS forecast for the fiscal quarter 2025 (Q3) is 4.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing